****

**Fig S2. MM patients’ malignant PCs treated with Bortezomib and Lenalidomide do not express augmented levels of the IL-15/IL-15R complex**

(A) BMMCs were cultured without (NT) or with Lenalidomide (LENA), Bortezomib (BOR), or with melphalan (MEL) used as control, for 48h and the expression of IL-15 and IL-15RA was analyzed by immunofluorescence and flow cytometry gating on CD138+/CD38+ cells. Result from a representative patient is shown. (B) The average of four different patients is shown. ns=not significant